Andrea Dohlman, APRN
Adult Health · Rogers, ARNPI 1255737359
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 166 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,525, 5.1 times the $298 reported in 2021.
Across 166 payments — averaging $21.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$758
- Novo Nordisk$292
- Tandem Diabetes Care, Inc.$284
- Boehringer Ingelheim$201
- Insulet Corporation$189
- Medtronic$188
- plus $2K from 23 others
What the payments were for
- Food & beverage$3,41498%
- Education$752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 31 | $758 |
| Novo Nordisk | 21 | $292 |
| Tandem Diabetes Care, Inc. | 12 | $284 |
| Boehringer Ingelheim | 11 | $201 |
| Insulet Corporation | 8 | $189 |
| Medtronic | 9 | $188 |
| Lilly USA, LLC | 10 | $175 |
| Sanofi-aventis U.S. LLC | 8 | $143 |
| Corcept Therapeutics | 6 | $137 |
| Cequr Corporation | 2 | $126 |
| Mannkind Corporation | 3 | $105 |
| Abbott | 6 | $101 |
| Amgen | 6 | $98 |
| Sequel Med Tech, LLC | 4 | $92 |
| AbbVie | 4 | $88 |
| Ascendis Pharma Endocrinology Inc | 4 | $79 |
| Radius Health, Inc. | 3 | $68 |
| Averitas Pharma Inc. | 3 | $65 |
| Recordati_rare_diseases_inc. | 2 | $56 |
| Antares Pharma, Inc. | 3 | $50 |
| Acella Pharmaceuticals, LLC | 2 | $37 |
| Neurocrine Biosciences, Inc. | 1 | $27 |
| Chiesi USA, Inc. | 1 | $26 |
| Ascensia Diabetes Care US Inc. | 1 | $20 |
| Bayer | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| AstraZeneca | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Boston Scientific | 1 | $13 |
How this compares
$3,489 in reported general payments places this provider in the 85th percentile of 154 adult health providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 108 | $179,972 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 76 | $101,901 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 88 | $95,806 |
| OzempicSemaglutide | 33 | $55,380 |
| JardianceEmpagliflozin | 53 | $49,199 |
| MounjaroTirzepatide | 32 | $48,976 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $37,278 |
| FarxigaDapagliflozin Propanediol | 23 | $28,470 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $27,757 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 27 | $27,168 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 24 | $24,422 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $20,329 |
| Xigduo XrDapaglifloz Propaned/Metformin | 21 | $19,582 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $19,064 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 105 | $13,355 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskXultophy 100-3.6, Ozempic | $292 | $235,352141 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance | $201 | $145,005141 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $143 | $101,90176 claims |
| Lilly USA, LLCMounjaro | $175 | $48,97632 claims |
| AstraZenecaFarxiga | $17 | $28,47023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 154 adult health providers in Arkansas.
Other adult health in Rogers
- Megan WebbRogers$1K
- Starry Taylor HubbellRogers$1K
- Candy AulerRogers$970
- Holly MooreLittle Rock$59K
- Deborah ShipmanJonesboro$41K
- Lisa HurdJonesboro$12K
- Kari SchrankFayetteville$9K
- Amanda McClureFayetteville$9K
- Gina NullFort Smith$8K
- Darren CompasBentonville$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.